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that insulin-sensitive GLUT8 plays a prominent role in maintaining neuronal glucose homeostasis [8] . While GLUT2 is of extreme importance at the periphery for glucose sensing by the insulin producing/secreting cells, it remains a poorly investigated GLUT isoform within the brain. It is a low affinity, high-volume glucose transporter, which at the periphery is localized mainly on the membrane of the pancreatic β cells; coupling with glucokinase causes a glucose-sensing mechanism providing high-capacity glucose transport into cell and triggers insulin secretion [9] . Low levels of GLUT2 have also been found in the mammalian brain [3, 10] .
GLUT2-immunoreactive signalling was found throughout the brain especially in limbic areas
and related nuclei, and appeared to be most concentrated in the ventral and medial regions close to the midline [11] . Few oligodendrocyte and astrocyte cell bodies were found to be labelled with GLUT2 in large myelinated fibre bundles, whereas the reactive glial processes have more numerous amounts and are often localized in the vicinity of nerve terminals and/or dendrites or dendritic spines forming synaptic contacts [12] . As a result, it has been suggested that GLUT2 might participate in the regulation of neurotransmitter release and, perhaps, in the release of glucose by glial cells. Nerve cell bodies immunostained for GLUT2 are scarce (although numerous in the dentate gyrus granular layer); whereas in the periphery, numerous nerve cells are labelled for this transporter [12] . The latter are clustered in the dorsal endopiriform nucleus and neighbouring temporal and perirhineal cortex, in the dorsal amygdaloid region, and in the paraventricular and reuniens thalamic nuclei, and only a few in the hypothalamus.
It has been hypothesized that GLUT2, at least partially, is involved in cerebral glucose sensing [13] . The phenotype of glucose sensing neurons is similar to the pancreatic β cells in that these specialized neurons express sulfonylurea receptors, the pore forming subunit of the ATP-sensitive K + channel and glucokinase, all allowing speculation that GLUT2 may serve a similar role in pancreatic β cells and in glucose sensing neurons, including the induction of insulin secretion [14] . This hypothesis is supported by the finding that the release of insulin from brain synaptosomes is stimulated by glucose [15] .
Therefore, it seems likely that cerebral GLUT2 might also be involved in initiation of the insulin-induced actions within the brain.
GLUT2 mRNA distribution in the adult rat brain appears not to be entirely parallel to that of glucokinase [16] , suggesting participation of brain GLUT2 in functions other than glucose sensing and insulin secretion, which remain to be explored. Beside GLUTs 1-4 and partly GLUT8, the role of other GLUT isoforms in the brain has been far less explored and understood [3] .
Brain insulin system
Among other factors, cerebral glucose uptake/ metabolism seems to be under the control of the neuronal insulin signal transduction system, as briefly mentioned above. The effect of insulin on cerebral glucose metabolism in humans has been extensively studied during the last two decades, but still remains controversial. In the mature adult brain the majority of insulin originates from the periphery, crossing the blood-brain barrier, while a smaller proportion of insulin is produced within the brain itself, as reviewed elsewhere [17, 18] . Insulin in the brain binds to the neuronal insulin receptors which are abundantly but selectively distributed, with the highest concentration in the nerve terminals of key brain regions, such as the olfactory bulb, hypothalamus, cerebral cortex, cerebellum and hippocampus [19] [20] [21] [22] in the hippocampus [3, 7] . Since hippocampal glucoregulatory activities contribute to cognitive function [30] , insulin modulation of glucose metabolism in this structure appears to be one of the key components of hippocampal vulnerability.
Brain glucose transporters and alzheimer's disease
Humans. The pathophysiology of GLUT isoforms in sAD is not well understood as there are only few literature reports on this issue.
Reduced densities of GLUT1 and GLUT3 have been consistently found post-mortem in the brain of AD patients [31] [32] [33] [34] [35] . It has been suggested that the decrease in GLUT1 and GLUT3 levels in AD patients may result from down-regulation of hypoxia-inducible factor-1 (HIF-1) in AD patients, as it is involved in the regulation of GLUT1 and GLUT3 expression [34] . Furthermore, the decrease in GLUT1
and GLUT3 levels have been correlated to a decrease in 0-GlcNAcylation and to the hyperphosphorylation of tau protein in 7 AD brains post mortem with Braak stage V-VI [34] . This is in line with a previous finding that 0-GlcNAcylation and phosphorylation of tau regulate each other reciprocally [36] .
Interestingly, in the brain of AD patients no change in GLUT4 levels and a significant increase in GLUT2 levels were found [38] . The [39] . In another transgenic AD mice model (APP/PS1 transgenic mice) reduced levels of GLUT1 were found in the hippocampus (highest in the dentate gyrus) at age of 18 months with no differences in capillary density;
while at 8 months, no differences were observed [40] . The authors concluded that the GLUT-1 amount and capillary density in both wild type and transgenic mice decreased due to ageing and that β-amyloid load in the hippocampus preceded the reduction of GLUT- 
peripheral administration of streptozotocin and glucose transporters
Streptozotocin (STZ, chemically (2-deoxy-2-(3- [50] and an increase in the total number of insulin receptors, but with little change in the phosphorylated insulin receptor-β subunit [51] . Selective toxicity for insulin producing/secreting cells in the pancreas is related to the selective uptake of STZ via the glucose transporter GLUT2, which is predominantly located on the pancreatic β cell membrane [48] . The important role of GLUT2 has been confirmed with reports of the prevention of STZ-induced diabetogenic action by reduction of GLUT2 expression [52, 53] . In line with that, the sensitivity of pancreatic β cells to STZ toxicity seems to be species-specific, and related to species-dependent difference in the levels of GLUT2 expression. Namely, human β cells express lower levels of GLUT2 than rodent islets and are much more resistant to STZ than mice and rats [54] . Furthermore, STZ has been shown to be a substrate for GLUT2-type only, as in vitro culture of islets of transgenic mice expressing only GLUT1-type has been shown to be insensitive to STZ toxicity [55] .
However, not only has STZ been a selective substrate for GLUT2, but in vitro studies have also demonstrated that GLUT2 itself is a key target molecule for STZ, as the drug reduces GLUT2 protein expression in a concentrationdependent manner [56] . Once STZ has entered the cell, this nitrosourea drug is metabolized to liberate nitric oxide which is further involved in DNA alkylation and fragmentation followed by the unfavourable activation of the nuclear poly(ADP-ribose) polymerase, resulting in depletion of cellular NAD+ and ATP stores [48, 57] . [66, 67] . However, one should be aware that there is no substrate selectivity of 5-TG and 3-0MG for the GLUT2 isoform among other GLUTs [71] . As a result, 5-TG and 3-0MG may compete with glucose transport via other GLUT isoforms (like GLUT1 and GLUT3 and cognitive impairment in rats, strongly supports our hypothesis [73, 74] . In line with the experimental data that reduced GLUT2 levels are responsible for STZ insensitivity [54] , the only published data on increased GLUT2 levels found in AD patients post mortem due to astrocyte activation [34] may suggest increased sensitivity and vulnerability of GLUT2 expressing neurons in AD. The research in progress will hopefully elucidate the pathophysiological role of GLUT2 in sAD etiopathogenesis.
